Session Information
-
WCLC 2022
2022 World Conference on Lung Cancer
Conference Program for 2022 the World Conference on Lung Cancer
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2137
All times listed are in Vienna, Austria Time, CEST (UTC+2:00)
PL - Plenary
IBS - Interactive Breakfast Session (in-person attendees only)
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
P - Posters
EP - ePosters
WS - Workshops
LA – Lectureship Awards
IS - Industry Symposium
August 5 Fri
Aug 5 Saturday
August 6 Sat
Aug 6 Sunday
August 7 Sun
Aug 7 Monday
August 8 Mon
Aug 8 Tuesday
August 9 Tue
Aug 9
-
+
MA02 - Molecular Underpinnings of Lung Cancer Histological Differentiation and Targeted Therapeutics
- 10:45 - 11:45
- 8/07/2022
- Location: Hall C8
- Not for CME Credit
- Type: Mini Oral
- Track: Tumor Biology and Biomarkers
- Moderators:Erik Thunnissen, Rafael Rosell
-
+
Session Moderator
10:45 - 10:45 | Presenter: Erik Thunnissen
- Abstract
Loading... -
+
Session Moderator
10:45 - 10:45 | Presenter: Rafael Rosell
- Abstract
Loading... -
+
MA02.01 - Session Introduction
10:45 - 10:46 | Presenter: Erik Thunnissen
- Abstract
Loading... -
+
MA02.02 - Session Introduction
10:46 - 10:47 | Presenter: Rafael Rosell
- Abstract
Loading... -
+
MA02.03 - The Evolution of Lung Neuroendocrine Tumors
10:47 - 10:52 | Presenter: Nicolas Alcala
- Abstract
Loading... -
+
MA02.04 - Molecular Drivers and Therapeutic Targets for Neuroendocrine Transformation in Lung Cancer
10:52 - 10:57 | Presenter: Triparna Sen
- Abstract
Loading... -
+
MA02.05 - Dynamic Mutation Profiles of SCLC Transformation in NSCLC Patients Harboring Concurrent EGFR/TP53/RB1 Mutations
10:57 - 11:02 | Presenter: Jie Huang
- Abstract
Loading... -
+
MA02.06 - Discussant
11:02 - 11:12 | Presenter: Yuko Minami
- Abstract
Loading... -
+
MA02.07 - Aurora A Kinase Inhibition with VIC-1911Potentiates KRASG12C Inhibitor and Overcomes Resistance to Sotorasib in Lung Cancer
11:12 - 11:17 | Presenter: Jong Woo Lee
- Abstract
Loading... -
+
MA02.08 - Trametinib Inhibition of MEK1 2 Upregulates PD-L1 Expression in KRAS-Mutant NSCLC Through ID1 Downregulation
11:17 - 11:22 | Presenter: Ander Puyalto
- Abstract
Loading... -
+
MA02.09 - Impact of Baseline Clinicopathologic and Genomic Features on Outcomes to KRAS G12C Inhibitors in Patients with NSCLC
11:22 - 11:27 | Presenter: Giuseppe Lamberti
- Abstract
Loading... -
+
MA02.10 - Discussant
11:27 - 11:37 | Presenter: Sally Lau
- Abstract
Loading... -
+
MA02.11 - Live Q&A
11:37 - 11:45
- Abstract
Loading...
-
+
EP05.01 - Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy
-
+
EP05.01-001 - Hispanic Patients with Unresectable Stage III NSCLC under PACIFIC Protocol: Evidence of Interior Outcomes and Health Inequity
Presenter: Andres F Cardona- Abstract
Loading...
-
+
EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
-
+
EP08.02-011 - Design of a Phase I Trial (TOTEM) to Test Repotrectinib in Combination with Osimertinib in Advanced, Metastatic EGFR-Mutant NSCLC
Presenter: Andrés Aguilar- Abstract
Loading... -
+
EP08.02-032 - High Efficiency Multiplex Detection of Molecular Alterations in Supernatants of Pleural Effusion and Cerebrospinal Fluid
Presenter: Clara Mayo de las Casas- Abstract
Loading... -
+
EP08.02-120 - MET Alterations at Presentation in NSCLC Patients Harboring EGFR Mutations and ALK, RET and ROS1 fusions
Presenter: Núria Jordana- Abstract
Loading... -
+
EP08.02-135 - Anti-EGF Antibodies Significantly Improve the Activity of MET and KRAS Inhibitors in Preclinical Models of Non-small Cell Lung Cancer (NSCLC)
Presenter: Silvia Garcia-Roman- Abstract
Loading... -
+
EP08.02-159 - Post Hoc Analyses of Dacomitinib-Associated Skin Disorders and Efficacy in the ARCHER 1050 Study
Presenter: Lin Wu- Abstract
Loading...
-
+
EP16.02 - Tumor Biology and Biomarkers - Minimally Invasive Biomarkers
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Tumor Biology and Biomarkers - Minimally Invasive Biomarkers
-
+
EP16.02-007 - Detection of Clinically Relevant Fusions and Exon Skipping Alterations in Non Small Cell Lung Cancer Patients Liquid Biopsies
Presenter: Estela Sánchez-Herrero- Abstract
Loading...
-
+
EP16.03 - Tumor Biology and Biomarkers - Molecular Profiling and Targeted Therapeutics
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Tumor Biology and Biomarkers - Molecular Profiling and Targeted Therapeutics
-
+
EP16.03-002 - Mechanisms of Resistance to First-line Osimertinib in Hispanic Patients with EGFR mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP∫)
Presenter: Andres F Cardona- Abstract
Loading... -
+
EP16.03-003 - Systematic Population-based Identification of NTRK Fusion Genes Among Hispanic Patients with Non-Small Cell Lung Cancer (NSCLC)
Presenter: Andres F Cardona- Abstract
Loading...
